Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pleural Effusion, Malignant 4Breast Neoplasms 4Immunoglobulin Light-chain Amyloidosis 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Exanthema 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Urologic Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Tissue Adhesions 1Skin Toxicity 1Sezary Syndrome 1Ras-wildtype Colorectal Cancer 1Polyps 1Polycystic Ovary Syndrome 1Pain 1Ovarian Neoplasms 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasms 1Myoma 1Menstruation Disturbances 1Melanoma 1

Interventions

Sirolimus 9Everolimus 5Imatinib Mesylate 2temsirolimus 1saracatinib 1nintedanib 1carbon-11 acetate 1Valproic Acid 1Sugars 1Simvastatin 1Resveratrol 1Octreotide 1Loratadine 1Letrozole 1Immunoglobulin G 1Hydroxychloroquine 1Glutamine 1Doxycycline 1Disulfides 1Cetuximab 1Celecoxib 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphangioleiomyomatosis × Doxycycline × Clear all
NCT00989742 2015-12-02

Doxycycline In Lymphangioleiomyomatosis (LAM)

University of Nottingham

Phase 4 Completed
24 enrolled

Tuberous Sclerosis, Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡